Belumosudil Mesylate

CHEMBL4802130 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
548.6 g/mol
LogP
Phase
4

The mesylate salt of belumosudil, used to treat chronic graft-versus-host disease via the same ROCK2 inhibition mechanism as the parent compound.

Molekularmasse

548,6000 g/mol

TPSA

168,00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1.CS(=O)(=O)O

InChI

InChI=1S/C26H24N6O2.CH4O3S/c1-16(2)28-24(33)15-34-20-7-5-6-17(13-20)25-30-23-9-4-3-8-21(23)26(31-25)29-19-10-11-22-18(12-19)14-27-32-22;1-5(2,3)4/h3-14,16H,15H2,1-2H3,(H,27,32)(H,28,33)(H,29,30,31);1H3,(H,2,3,4)

Molecular Formula

C27H28N6O5S

HBD / HBA

4 / 9

Rotierbare Bindungen

7

Schwere Atome

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The mesylate salt of belumosudil, used to treat chronic graft-versus-host disease via the same ROCK2 inhibition mechanism as the parent compound.

Yes, Belumosudil Mesylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4802130. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 146025939. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.